Denmark· DK-28104883511
Temozolomid "Fair-Med"
A temozolomide product containing temozolomid, registered in Denmark by Fair-Med Healthcare GmbH. The same ATC class is registered in 17 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Temozolomide is registered in 17 of 19 countries.
Countries holding a registration under ATC L01AX03 (temozolomide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Temozolomide · ATC L01AX03
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of temozolomide costs, country by country.
Normalised to the WHO defined daily dose (65 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Temozolomide · price per daily dose (65 mg)
USD · FX 28 Sept 2026
- IT Italy$43.87
- CH Switzerland$34.49
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- TEMOZOLOMID
- Manufacturer
- Fair-Med Healthcare GmbH
- Country
- Denmark (DK)
- ATC code
- L01AX03
- ATC class
- Temozolomide
- Defined daily dose
- 65 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104883511
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
354 interactions on record for temozolomide.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Temozolomide · interactions on record
354 records
- 33 severe
- 103 moderate
- 16 minor
- 202 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01AX03
Temozolomide, as other registers publish it.
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- CanadaACH-TEMOZOLOMIDEACCORD HEALTHCARE INC
- NetherlandsBlastomat 100 mg, harde capsulesZentiva k.s.
- NetherlandsBlastomat 140 mg, harde capsulesZentiva k.s.
- NetherlandsBlastomat 180 mg, harde capsulesZentiva k.s.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef2c6814-e11a-45fa-bd5a-77e503c0e8eb GET /v1/drugs/ef2c6814-e11a-45fa-bd5a-77e503c0e8eb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, hårde",
"source": "dkma",
"strength": "5 mg",
"auth_role": "CMS",
"dk_drugid": "28104883511",
"substance": "TEMOZOLOMID",
"auth_procedure": "Decentral procedure",
"in_medicinpriser": false,
"registration_date_serial": "41297"
}See everything about temozolomide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.